Celgene invested $30M in NantCell weeks before BMS bid

NantCell said Celgene Corp. (NASDAQ:CELG) invested $30 million through a crossover round, valuing NantCell at $4 billion. The investment, which closed Dec. 19, brings Celgene's total investment in the immunotherapy company to $105 million for a 2.8% ownership stake.